BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nakano J, Huang C, Liu D, Masuya D, Nakashima T, Yokomise H, Ueno M, Wada H, Fukushima M. Evaluations of biomarkers associated with 5-FU sensitivity for non-small-cell lung cancer patients postoperatively treated with UFT. Br J Cancer 2006;95:607-15. [PMID: 16880781 DOI: 10.1038/sj.bjc.6603297] [Cited by in Crossref: 43] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
Number Citing Articles
1 Himuro N, Niiya Y, Minakata T, Oshima Y, Kataoka D, Yamamoto S, Suzuki T, Kadokura M. Thymidine phosphorylase affects clinical outcome following surgery and mRNA expression levels of four key enzymes for 5-fluorouracil metabolism in patients with stage I and II non-small cell lung cancer. Mol Clin Oncol 2018;9:640-6. [PMID: 30546894 DOI: 10.3892/mco.2018.1726] [Reference Citation Analysis]
2 Sakaguchi I, Motohara T, Saito F, Takaishi K, Fukumatsu Y, Tohya T, Shibata S, Mimori H, Tashiro H, Katabuchi H. High-dose oral tegafur-uracil maintenance therapy in patients with uterine cervical cancer. J Gynecol Oncol 2015;26:193-200. [PMID: 25686399 DOI: 10.3802/jgo.2015.26.3.193] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
3 Gotanda K, Hirota T, Matsumoto N, Ieiri I. MicroRNA-433 negatively regulates the expression of thymidylate synthase (TYMS) responsible for 5-fluorouracil sensitivity in HeLa cells. BMC Cancer 2013;13:369. [PMID: 23915286 DOI: 10.1186/1471-2407-13-369] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 4.5] [Reference Citation Analysis]
4 Zhao HY, Huang H, Hu ZH, Huang Y, Lin SX, Tian Y, Lin TY. Evaluations of biomarkers associated with sensitivity to 5-fluorouracil and taxanes for recurrent/advanced breast cancer patients treated with capecitabine-based first-line chemotherapy. Anticancer Drugs 2012;23:534-42. [PMID: 22481060 DOI: 10.1097/CAD.0b013e32834f7ef4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
5 Fujishima H, Fumoto S, Shibata T, Nishiki K, Tsukamoto Y, Etoh T, Moriyama M, Shiraishi N, Inomata M. A 17-molecule set as a predictor of complete response to neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal cancer. PLoS One 2017;12:e0188098. [PMID: 29136005 DOI: 10.1371/journal.pone.0188098] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
6 Igishi T, Shigeoka Y, Yasuda K, Suyama H, Katayama S, Sugitani A, Matsumoto S, Yamamoto M, Ueda Y, Takeda K, Sumikawa T, Sako T, Kodani M, Hitsuda Y, Shimizu E. UFT Plus Vinorelbine in Advanced Non-small Cell Lung Cancer: A Phase I and an Elderly Patient-Directed Phase II Study. Journal of Thoracic Oncology 2009;4:376-82. [DOI: 10.1097/jto.0b013e3181989dfc] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
7 Hamamoto Y, Takeoka S, Mouri A, Fukusumi M, Wakuda K, Ibe T, Honma C, Arimoto Y, Yamada K, Wagatsuma M, Tashiro A, Kamoshida S, Kamimura M. Orotate phosphoribosyltransferase is overexpressed in malignant pleural mesothelioma: Dramatically responds one case in high OPRT expression. Rare Dis 2016;4:e1165909. [PMID: 27274438 DOI: 10.1080/21675511.2016.1165909] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
8 Lee BR, Yu JY, Yoon SH, Ban HJ, Kwon YS, Oh IJ, Kim KS, Kim YI, Lim SC, Kim YC. Variability in the anti-tumor effect of tegafur-uracil depending on histologic types of lung cancer. J Thorac Dis 2015;7:433-8. [PMID: 25922722 DOI: 10.3978/j.issn.2072-1439.2015.01.22] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Mirza A, Naveed A, Hayes S, Formela L, Welch I, West CM, Pritchard S. Assessment of Histopathological Response in Gastric and Gastro-Oesophageal Junction Adenocarcinoma following Neoadjuvant Chemotherapy: Which Scoring System to Use? ISRN Pathology 2012;2012:1-8. [DOI: 10.5402/2012/519351] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
10 Wu WC, Liu YM, Liao YH, Hsu KC, Lien ST, Chen IC, Lai MJ, Li YH, Pan SL, Chen MC, Liou JP. Fluoropyrimidin-2,4-dihydroxy-5-isopropylbenzamides as antitumor agents against CRC and NSCLC cancer cells. Eur J Med Chem 2020;203:112540. [PMID: 32683166 DOI: 10.1016/j.ejmech.2020.112540] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Imai H, Shimizu K, Kawashima O, Endoh H, Imaizumi K, Goto Y, Kamiyoshihara M, Sugano M, Yamamoto R, Tanaka S, Fujita A, Kogure Y, Seki Y, Mogi A, Oyama T, Minato K, Asao T, Kaira K. Clinical Significance of Various Drug-Sensitivity Markers in Patients with Surgically Resected Pulmonary Pleomorphic Carcinoma. Cancers (Basel) 2019;11:E1636. [PMID: 31653009 DOI: 10.3390/cancers11111636] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
12 Sakamoto E, Nagase H, Kobunai T, Oie S, Oka T, Fukushima M, Oka T. Orotate phosphoribosyltransferase expression level in tumors is a potential determinant of the efficacy of 5-fluorouracil. Biochemical and Biophysical Research Communications 2007;363:216-22. [DOI: 10.1016/j.bbrc.2007.08.164] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
13 Takeda M, Okamoto I, Hirabayashi N, Kitano M, Nakagawa K. Thymidylate synthase and dihydropyrimidine dehydrogenase expression levels are associated with response to S-1 plus carboplatin in advanced non-small cell lung cancer. Lung Cancer 2011;73:103-9. [DOI: 10.1016/j.lungcan.2010.10.022] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
14 Gordon MS, Rosen LS, Mendelson D, Ramanathan RK, Goldman J, Liu L, Xu Y, Gerson SL, Anthony SP, Figg WD, Spencer S, Adams BJ, Theuer CP, Leigh BR, Weiss GJ. A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors. Invest New Drugs 2013;31:714-23. [PMID: 23054206 DOI: 10.1007/s10637-012-9876-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
15 Kaira K, Ohde Y, Nakagawa K, Okumura T, Murakami H, Takahashi T, Kondo H, Nakajima T, Endo M, Yamamoto N. Thymidylate synthase expression is closely associated with outcome in patients with pulmonary adenocarcinoma. Med Oncol 2012;29:1663-72. [DOI: 10.1007/s12032-011-0069-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
16 Honma Y, Togo S, Shimizu K, Tulafu M, Hayashi T, Uekusa T, Tominaga S, Kido K, Fujimoto Y, Nanba Y, Takamochi K, Oh S, Suzuki K, Takahashi K. Expression of thymidylate synthase predicts clinical outcomes of S-1-based chemotherapy in squamous cell lung cancer. Oncol Lett 2017;14:3319-26. [PMID: 28927083 DOI: 10.3892/ol.2017.6610] [Reference Citation Analysis]
17 Hirota T, Date Y, Nishibatake Y, Takane H, Fukuoka Y, Taniguchi Y, Burioka N, Shimizu E, Nakamura H, Otsubo K, Ieiri I. Dihydropyrimidine dehydrogenase (DPD) expression is negatively regulated by certain microRNAs in human lung tissues. Lung Cancer 2012;77:16-23. [PMID: 22306127 DOI: 10.1016/j.lungcan.2011.12.018] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 5.0] [Reference Citation Analysis]
18 Sanada Y, Yoshida K, Ohara M, Tsutani Y. Expression of orotate phosphoribosyltransferase (OPRT) in hepatobiliary and pancreatic carcinoma. Pathol Oncol Res 2007;13:105-13. [DOI: 10.1007/bf02893485] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
19 Asai A, Konno M, Koseki J, Taniguchi M, Vecchione A, Ishii H. One-carbon metabolism for cancer diagnostic and therapeutic approaches. Cancer Lett 2020;470:141-8. [PMID: 31759958 DOI: 10.1016/j.canlet.2019.11.023] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
20 Liang YY, Bacanu S, Sreekumar L, Ramos AD, Dai L, Michaelis M, Cinatl J, Seki T, Cao Y, Coffill CR, Lane DP, Prabhu N, Nordlund P. CETSA interaction proteomics define specific RNA-modification pathways as key components of fluorouracil-based cancer drug cytotoxicity. Cell Chem Biol 2021:S2451-9456(21)00306-8. [PMID: 34265272 DOI: 10.1016/j.chembiol.2021.06.007] [Reference Citation Analysis]
21 Takashima T, Hara F, Iwamoto T, Uemura Y, Ohsumi S, Yotsumoto D, Hozumi Y, Watanabe T, Saito T, Watanabe KI, Tsurutani J, Toyama T, Akabane H, Nishimura R, Taira N, Ohashi Y, Mukai H. A Correlation Analysis Between Metabolism-related Genes and Treatment Response to S-1 as First-line Chemotherapy for Metastatic Breast Cancer: The SELECT BC-EURECA Study. Clin Breast Cancer 2021;21:450-7. [PMID: 33685834 DOI: 10.1016/j.clbc.2021.01.018] [Reference Citation Analysis]
22 Grimminger PP, Schneider PM, Metzger R, Vallböhmer D, Hölscher AH, Danenberg PV, Brabender J. Low thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase mRNA expression correlate with prolonged survival in resected non-small-cell lung cancer. Clin Lung Cancer 2010;11:328-34. [PMID: 20837458 DOI: 10.3816/CLC.2010.n.041] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
23 Abu Lila AS, Moriyoshi N, Fukushima M, Huang C, Wada H, Ishida T. Metronomic S-1 dosing and thymidylate synthase silencing have synergistic antitumor efficacy in a colorectal cancer xenograft model. Cancer Letters 2017;400:223-31. [DOI: 10.1016/j.canlet.2016.11.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
24 Eguchi K, Oyama T, Tajima A, Abiko T, Sawafuji M, Horio H, Hashizume T, Matsutani N, Kato R, Nakayama M, Kawamura M, Kobayashi K. Intratumoral gene expression of 5-fluorouracil pharmacokinetics-related enzymes in stage I and II non-small cell lung cancer patients treated with uracil-tegafur after surgery: a prospective multi-institutional study in Japan. Lung Cancer 2015;87:53-8. [PMID: 25468199 DOI: 10.1016/j.lungcan.2014.10.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
25 Li JA, Xu XF, Han X, Fang Y, Shi CY, Jin DY, Lou WH. Nab-Paclitaxel Plus S-1 Shows Increased Antitumor Activity in Patient-Derived Pancreatic Cancer Xenograft Mouse Models. Pancreas. 2016;45:425-433. [PMID: 26495780 DOI: 10.1097/mpa.0000000000000501] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
26 Nii K, Tokunaga Y, Liu D, Zhang X, Nakano J, Ishikawa S, Kakehi Y, Haba R, Yokomise H. Overexpression of G protein-coupled receptor 87 correlates with poorer tumor differentiation and higher tumor proliferation in non-small-cell lung cancer. Mol Clin Oncol 2014;2:539-44. [PMID: 24940491 DOI: 10.3892/mco.2014.292] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
27 Zhao HY, Chen GY, Huang Y, Li XL, Feng JF, Shi MQ, Cheng Y, Ma LX, Zhang YP, Gu CP, Song XQ, Zhou D, Zhang L. Erlotinib plus capecitabine as first-line treatment for older Chinese patients with advanced adenocarcinoma of the lung (C-TONG0807): an open-label, single arm, multicenter phase II study. Medicine (Baltimore) 2015;94:e249. [PMID: 25590835 DOI: 10.1097/MD.0000000000000249] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
28 Reddy AB, Manjula B, Jayaramudu T, Sadiku ER, Anand Babu P, Periyar Selvam S. 5-Fluorouracil Loaded Chitosan-PVA/Na+MMT Nanocomposite Films for Drug Release and Antimicrobial Activity. Nanomicro Lett 2016;8:260-9. [PMID: 30460286 DOI: 10.1007/s40820-016-0086-4] [Cited by in Crossref: 47] [Cited by in F6Publishing: 33] [Article Influence: 9.4] [Reference Citation Analysis]
29 Kaira K, Serizawa M, Koh Y, Miura S, Kaira R, Abe M, Nakagawa K, Ohde Y, Okumura T, Murakami H, Tsuya A, Nakamura Y, Naito T, Takahashi T, Kondo H, Nakajima T, Endo M, Yamamoto N. Expression of thymidylate synthase, orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in thymic epithelial tumors. Lung Cancer 2011;74:419-25. [DOI: 10.1016/j.lungcan.2011.04.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
30 Shimizu K, Yukawa T, Okita R, Saisho S, Maeda A, Nojima Y, Nakata M. Cyclooxygenase-2 expression is a prognostic biomarker for non-small cell lung cancer patients treated with adjuvant platinum-based chemotherapy. World J Surg Oncol 2015;13:21. [PMID: 25888998 DOI: 10.1186/s12957-014-0426-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
31 Wallerek S, Sørensen JB. Biomarkers for efficacy of adjuvant chemotherapy following complete resection in NSCLC stages I-IIIA. Eur Respir Rev 2015;24:340-55. [PMID: 26028645 DOI: 10.1183/16000617.00005814] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
32 Noro R, Miyanaga A, Minegishi Y, Okano T, Seike M, Soeno C, Kataoka K, Matsuda K, Yoshimura A, Gemma A. Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21(waf1/cip1) expression. Cancer Sci 2010;101:1424-30. [PMID: 20384633 DOI: 10.1111/j.1349-7006.2010.01559.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]